[
  {
    "ts": null,
    "headline": "Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. As monotherapy, imlunestrant demonstrated a clinically meaningful 38% reduction in the",
    "url": "https://finnhub.io/api/news?id=f61d7b755113947727656576f959180ff038eddba157f91be5f6fa24e737e64c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765557900,
      "headline": "Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer",
      "id": 137769271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. As monotherapy, imlunestrant demonstrated a clinically meaningful 38% reduction in the",
      "url": "https://finnhub.io/api/news?id=f61d7b755113947727656576f959180ff038eddba157f91be5f6fa24e737e64c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win",
    "summary": "LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.",
    "url": "https://finnhub.io/api/news?id=b219fac2558d26ecf380e490b1e8acf0097923ed1b21f46ba1b32ba9821b63a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765556220,
      "headline": "Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win",
      "id": 137769272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.",
      "url": "https://finnhub.io/api/news?id=b219fac2558d26ecf380e490b1e8acf0097923ed1b21f46ba1b32ba9821b63a9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10",
    "summary": "On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.",
    "url": "https://finnhub.io/api/news?id=9e48e2ca8b13005d788be20d90926ecd77938104f9249bf0950dd7e1c6df0bdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765555497,
      "headline": "Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10",
      "id": 137769273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.",
      "url": "https://finnhub.io/api/news?id=9e48e2ca8b13005d788be20d90926ecd77938104f9249bf0950dd7e1c6df0bdf"
    }
  },
  {
    "ts": null,
    "headline": "NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?",
    "summary": "Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.",
    "url": "https://finnhub.io/api/news?id=90e5c19a17f080fe13506d76d9fada2d8c8414b169de3e4d4e610ce2e36f55ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553820,
      "headline": "NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?",
      "id": 137769274,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.",
      "url": "https://finnhub.io/api/news?id=90e5c19a17f080fe13506d76d9fada2d8c8414b169de3e4d4e610ce2e36f55ed"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones, Russell 2000 Hit Highs, Buoyed By Fed; Oracle, Broadcom Weigh On Techs: Weekly Review",
    "summary": "The Dow Jones and Russell 2000 hit record highs this past week, buoyed by a Fed rate cut and dovish Fed Chief Powell. Broadcom and Oracle weighed on techs.",
    "url": "https://finnhub.io/api/news?id=b90627a580b3f5cba592b26f785e3a90e3900d0766cc130b712173d5e28ce7b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765552828,
      "headline": "Dow Jones, Russell 2000 Hit Highs, Buoyed By Fed; Oracle, Broadcom Weigh On Techs: Weekly Review",
      "id": 137769136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones and Russell 2000 hit record highs this past week, buoyed by a Fed rate cut and dovish Fed Chief Powell. Broadcom and Oracle weighed on techs.",
      "url": "https://finnhub.io/api/news?id=b90627a580b3f5cba592b26f785e3a90e3900d0766cc130b712173d5e28ce7b6"
    }
  },
  {
    "ts": null,
    "headline": "Rival Healthcare Proposals Fail in Senate",
    "summary": "A Democratic proposal to extend enhanced ACA subsidies failed in the Senate.  It’s just weeks to go until millions of Americans covered under the Affordable Care Act face soaring costs for their coverage when the subsidies lapse.  The shift is a huge departure from how pharma companies have sold drugs for decades and threatens the multibillion-dollar business of firms that have traditionally filled prescriptions.",
    "url": "https://finnhub.io/api/news?id=8a29dc3016df644de87334503a09fd26341f309cb16237f7be700f7085045d9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765551300,
      "headline": "Rival Healthcare Proposals Fail in Senate",
      "id": 137769277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Democratic proposal to extend enhanced ACA subsidies failed in the Senate.  It’s just weeks to go until millions of Americans covered under the Affordable Care Act face soaring costs for their coverage when the subsidies lapse.  The shift is a huge departure from how pharma companies have sold drugs for decades and threatens the multibillion-dollar business of firms that have traditionally filled prescriptions.",
      "url": "https://finnhub.io/api/news?id=8a29dc3016df644de87334503a09fd26341f309cb16237f7be700f7085045d9e"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic launches in India at $24 a week as Novo targets booming market",
    "summary": "STORY: Novo Nordisk launched Ozempic in India on Friday (December 12).The Danish drugmaker priced the weight-loss drug at just over $24 per week for a 0.25 mg dose.Novo is targeting a booming diabetes and obesity market in the country.India has the world’s second-largest population of type 2 diabetes patients after China, and rising obesity rates.That has turned it into a key battleground for weight-loss drugsOzempic has become a global bestseller and is widely used for weight loss.Novo has said the drug also lowers the risk of cardiovascular events and kidney issues.Friday's update is a bright spot in a challenging year for Novo.It has faced strong competition from U.S. rival Eli Lilly and seen its share price drop heavily.",
    "url": "https://finnhub.io/api/news?id=99067bd15af8ab7aecf8ffc6cb4845d997d4baf80db66339a4bf25e9b8417210",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765548056,
      "headline": "Ozempic launches in India at $24 a week as Novo targets booming market",
      "id": 137768308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk launched Ozempic in India on Friday (December 12).The Danish drugmaker priced the weight-loss drug at just over $24 per week for a 0.25 mg dose.Novo is targeting a booming diabetes and obesity market in the country.India has the world’s second-largest population of type 2 diabetes patients after China, and rising obesity rates.That has turned it into a key battleground for weight-loss drugsOzempic has become a global bestseller and is widely used for weight loss.Novo has said the drug also lowers the risk of cardiovascular events and kidney issues.Friday's update is a bright spot in a challenging year for Novo.It has faced strong competition from U.S. rival Eli Lilly and seen its share price drop heavily.",
      "url": "https://finnhub.io/api/news?id=99067bd15af8ab7aecf8ffc6cb4845d997d4baf80db66339a4bf25e9b8417210"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stumbles as Obesity Drug Race Heats Up",
    "summary": "Europe's former pharma king is in freefall as Eli Lilly tightens its grip and investors demand answers.",
    "url": "https://finnhub.io/api/news?id=e5577a955922fd393dde5883ee95083e5c64600a14aa7c76255ed5697762ac7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765545527,
      "headline": "Novo Nordisk Stumbles as Obesity Drug Race Heats Up",
      "id": 137768311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Europe's former pharma king is in freefall as Eli Lilly tightens its grip and investors demand answers.",
      "url": "https://finnhub.io/api/news?id=e5577a955922fd393dde5883ee95083e5c64600a14aa7c76255ed5697762ac7a"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Rise, Techs Fall; Broadcom Latest AI Giant To Tumble On Earnings",
    "summary": "The Dow Jones and Russell 2000 hit record highs while the Nasdaq slashed early losses. Broadcom sees AI chip sales doubling.",
    "url": "https://finnhub.io/api/news?id=5cae30a60f029f0c894046e74757858c202643f0703dd3798580e96721efc803",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765544052,
      "headline": "Dow Jones Futures Rise, Techs Fall; Broadcom Latest AI Giant To Tumble On Earnings",
      "id": 137766697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones and Russell 2000 hit record highs while the Nasdaq slashed early losses. Broadcom sees AI chip sales doubling.",
      "url": "https://finnhub.io/api/news?id=5cae30a60f029f0c894046e74757858c202643f0703dd3798580e96721efc803"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock",
    "summary": "AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.",
    "url": "https://finnhub.io/api/news?id=a0611ee8f2fae54ea2e1e0c86e885f7f72f86bdab0218bfc361e63d6342dbd0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765543320,
      "headline": "AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock",
      "id": 137769283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.",
      "url": "https://finnhub.io/api/news?id=a0611ee8f2fae54ea2e1e0c86e885f7f72f86bdab0218bfc361e63d6342dbd0c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial",
    "summary": "Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.",
    "url": "https://finnhub.io/api/news?id=b1aeec2c77e22dd8298cc4d69cf1b1dc605cb60e5dc9f15d05845b528960492f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765542546,
      "headline": "Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial",
      "id": 137766848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.",
      "url": "https://finnhub.io/api/news?id=b1aeec2c77e22dd8298cc4d69cf1b1dc605cb60e5dc9f15d05845b528960492f"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026",
    "summary": "Eli Lilly's (LLY) experimental weight-loss pill orforglipron may receive US Food and Drug Administra",
    "url": "https://finnhub.io/api/news?id=59bc1e72a3931387da0d5a3f9addf053d75f6cdeefa3c02605b91c717f92f457",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765541962,
      "headline": "Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026",
      "id": 137766849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's (LLY) experimental weight-loss pill orforglipron may receive US Food and Drug Administra",
      "url": "https://finnhub.io/api/news?id=59bc1e72a3931387da0d5a3f9addf053d75f6cdeefa3c02605b91c717f92f457"
    }
  },
  {
    "ts": null,
    "headline": "Think Eli Lilly Is Expensive? This Metric Says Otherwise.",
    "summary": "The pharmaceutical stock can still deliver.",
    "url": "https://finnhub.io/api/news?id=8e99eb29d121dd3e437d5e1b49ba6647d3a2fb0be799294fc5e8493d23c47210",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765540920,
      "headline": "Think Eli Lilly Is Expensive? This Metric Says Otherwise.",
      "id": 137766850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical stock can still deliver.",
      "url": "https://finnhub.io/api/news?id=8e99eb29d121dd3e437d5e1b49ba6647d3a2fb0be799294fc5e8493d23c47210"
    }
  },
  {
    "ts": null,
    "headline": "Why a Budding Drug-Price Revolution Isn’t Quite What it Seems",
    "summary": "Companies like Cigna and CVS are promising simpler prices, but the behind-the-scenes system remains complex.",
    "url": "https://finnhub.io/api/news?id=730e77ef2dda2f9bf053083472012c017f0e1cd67b01006d34a79f7154999bc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765535400,
      "headline": "Why a Budding Drug-Price Revolution Isn’t Quite What it Seems",
      "id": 137766851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies like Cigna and CVS are promising simpler prices, but the behind-the-scenes system remains complex.",
      "url": "https://finnhub.io/api/news?id=730e77ef2dda2f9bf053083472012c017f0e1cd67b01006d34a79f7154999bc8"
    }
  },
  {
    "ts": null,
    "headline": "High-end Swiss chocolatier Läderach rules out U.S. production despite tariff shock",
    "summary": "The chocolate maker makes its products exclusively in its home country as \"consumers want Swiss chocolates to be made in Switzerland.\"",
    "url": "https://finnhub.io/api/news?id=9a9318c3129acc148bd7856925634b1e9064c6a7d1197b30365abada140c61d2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765527033,
      "headline": "High-end Swiss chocolatier Läderach rules out U.S. production despite tariff shock",
      "id": 137768867,
      "image": "https://image.cnbcfm.com/api/v1/image/108241160-1765544359707-gettyimages-2227876216-SWISS_GOODS_US.jpeg?v=1765544420&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The chocolate maker makes its products exclusively in its home country as \"consumers want Swiss chocolates to be made in Switzerland.\"",
      "url": "https://finnhub.io/api/news?id=9a9318c3129acc148bd7856925634b1e9064c6a7d1197b30365abada140c61d2"
    }
  },
  {
    "ts": null,
    "headline": "Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments",
    "summary": "The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.",
    "url": "https://finnhub.io/api/news?id=80b45f1ac8f46ef1ada7f6806c41bf7120c6f68b868188047d9204780da1925c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765515660,
      "headline": "Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments",
      "id": 137766852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.",
      "url": "https://finnhub.io/api/news?id=80b45f1ac8f46ef1ada7f6806c41bf7120c6f68b868188047d9204780da1925c"
    }
  }
]